To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
The MMRV vaccine combines the attenuated virus MMR (measles, mumps, rubella) vaccine with the addition of chickenpox vaccine.
One MMRV vaccine, approved in 2005 for use in the United States by the Food and Drug Administration for children ages twelve months through twelve years, is called ProQuad. The vaccine is administered via injection for protection against four viral infectious diseases, and contains about ten times more chickenpox vaccine than the Varivax brand varicella vaccine. The quadruple vaccine, marketed by pharmaceutical giant Merck, is generally administered to children around the age of one year.
Additional recommended knowledge
The World Health Organization recommends vaccinating against measles, mumps, rubella (German measles), and varicella (chickenpox) because the risks of these diseases far outweigh the risks of vaccinating against them. In particular, the World Health Organization recommends varicella vaccination in countries where the vaccine is affordable, the disease is a relatively important problem, and high and sustained coverage can be achieved. The U.S. and a few other countries have widely implemented this. MMR and varicella vaccine are given at roughly the same time and a booster injection is recommended for both. The MMRV vaccine, a combined MMR and varicella vaccine, simplifies administration of the vaccines.
In May, 2007, the manufacturer Merck announced that, due to manufacturing problems in the chickenpox component, the Merck vaccine ProQuad is not available. In August 2007, Merck announced that they did not know whether ProQuad would be made available in 2008 due to an issue with its bulk manufacturing process, but their goal was to restore its availability as soon as possible.
Doctors are advised to be aware of whether or not a patient has HIV, AIDS or another disease that affects the immune system, is taking a medication that affects the immune system, has cancer, a fever or active untreated tuberculosis, is receiving cancer treatment, or has ever had a low platelet count (a blood disorder). ·
Rare but serious adverse events reported following ProQuad vaccination include allergic reactions, including swelling of the lips, tongue, or face; difficulty breathing or closing of the throat; hives; paleness; weakness; dizziness; a fast heart beat; deafness; long-term seizures, coma, or lowered consciousness; permanent brain damage; seizures (jerking or staring) caused by fever; or temporary low platelet count. According to information from CDC, MMRV vaccine has been associated with higher rates of fever (up to about 1 person in 5) and measles-like rash (about 1 person in 20) compared with MMR and varicella vaccines given separately.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MMRV_vaccine". A list of authors is available in Wikipedia.|